Aurinia Pharmaceuticals Inc.
AUPH
$0.10
Change (1 day)
$10.05
Year High
$4.71
Year Low
Categories
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Earnings for Aurinia Pharmaceuticals Inc. (AUPH)
Earnings in 2023 (TTM): $-77,469,000
According to Aurinia Pharmaceuticals Inc.'s latest financial reports the company's current earnings (TTM) are $-77,469,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Aurinia Pharmaceuticals Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-77,469,000 | $-78,020,000 |
| 2022 | $-106,352,000 | $-108,180,000 |
| 2021 | $-180,206,000 | $-180,966,000 |
| 2020 | $-102,774,000 | $-102,680,000 |
| 2019 | $-123,702,000 | $-123,846,000 |
| 2018 | $-64,047,000 | $-64,120,000 |
| 2017 | $-70,792,000 | $-70,792,000 |
| 2016 | $-23,295,000 | $-23,295,000 |
| 2015 | $-18,607,000 | $-18,607,000 |
| 2014 | $-16,647,000 | $-16,647,000 |
| 2013 | $-6,402,322 | $-2,546,090 |
| 2012 | $-9,738,347 | $-9,737,342 |
| 2011 | $-2,407,444 | $-2,407,444 |
| 2010 | $-5,459,127 | $-3,660,414 |
| 2009 | $-7,598,128 | $-7,598,128 |
| 2008 | $-15,881,676 | $-15,881,676 |
| 2007 | $-33,822,074 | $-33,822,074 |
| 2006 | $-22,853,466 | $-22,852,608 |
| 2005 | $-29,074,393 | $-29,075,254 |
| 2004 | $-22,556,441 | $-22,559,768 |
| 2003 | $-14,519,923 | $-14,646,391 |
| 2002 | $-294,097 | $-365,875 |
| 2001 | $-7,349,339 | $-7,404,616 |
| 2000 | $-6,271,210 | $-6,284,888 |
| 1999 | $ | $-1,222,378 |
| 1998 | $-2,343,750 | $-2,213,542 |